Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity

Liver Transplantation

Volumn 14, Issue 6, 2008, Pages 815-822

  DiMartini, Andrea ^a,b   Fontes, Paulo ^a   Dew, Mary Amanda ^a   Lotrich, Francis E ^a   de Vera, Michael ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LIVER FAILURE; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROTOXICITY; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; TACROLIMUS;

EID: 46049118014     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21427     Document Type: Article

References (21)

1. Starzl TE. Back to the future. Transplantation 2005;79: 1009-1014.
2. Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991;23:3105-3108.
3. Bechstein WO. Neuroto)dcity of calcineurin inhibitors: impact and clinical management. Transpl. Int 2000; 13:313-326.
4. Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A, et al. Neurologic complications of FK 506. Transplant Proc 1991;23:3175-3178.
5. DiMartini A, Pajer K, Trzepacz P, Fung J, Starzl T, Tringali R. Psychiatric morbidity in liver transplant patients. Transplant Proc 1991;23:3179-3180.
6. DiMartini A, Trzepacz P, Pajer K, Fung J, Starzl T. Psychiatric side effects in alcoholic liver transplant patients: FK506 vs. cyclosporine. Paper presented at: American Psychiatric Association Symposium on Liver Transplant Patients; May 1992; Washington, DC.
7. Kanwal F, Chen D, Ting L, Gornbein J, Saab S, Durazo F, et al. A model to predict the development of mental status changes of unclear cause after liver transplantation. Liver Transpl 2003;9:1312-1319.
8. Toescu EC. Normal brain ageing: models and mechanisms. Philos Trans R Soc Lond B Biol Sci 2005;360:2347-2354.
9. Jain A, Brody D, Hamad I, Rishi N, Kanal E, Fung J. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. Transplantation 2000;69:172-176.
10. Wijdicks EF, Wiesner RH, Dahlke LJ, Krom PA. FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994;35:498-501.
11. Burkhalter EL, Starzl TE, Van Thiel DH. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. J Hepatol 1994;21:572-577.
12. DiMartini A, Trzepacz P, Daviss S. Prospective study of FK506 side effects: anxiety or akathisia? Biol Psychiatry 1996;40:407-411.
13. Kilinc M, Benli S, Can U, Yilmaz A, Karakayali H, Colak T, et al. FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. Transplant Proc 2002;34:1182-1184.
14. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122:128-134.
15. Sokol DK, Molleston JP, Filo, RS, Van Valer J, Edwards-Brown M. Tacrolimus (FK506)-induced mutism after liver transplant. Pediatr Neurol 2003:28:156-158.
16. Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004;39:1731-1738.
17. Shah GN, Mooradian AD. Age-related changes in the blood-brain barrier. Gerontology 1997;32:501-519.
18. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003;34:806-812.
19. Sorrell JH, Zolnikov BJ, Sharma A, Jinnai I. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci 2006;60:174-181.
20. Health Resources and Services Administration. 2006 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1996-2005. Available at: http://www.optn.org/AR2006/default.htm. Accessed January 2008.
21. Mueller AR, Platx KP, Bechstein WO, Schattenfroth N, Stoltenberg-Didinger G, Blumhardt G, et al. Neurotoxicity after orthotopic liver transplantation. Transplantation 1994;58:155-169.